In addition, we found that tRF-5014a, the most obviously differentially expressed tRF, contributes to inducing cardiomyocyte dysfunction by regulating ATG5 expression under HG conditions, suggesting that targeting tRFs might be a beneficial therapy for ameliorating DCM. This evidence concerns the gene ATG5 and familial dilated cardiomyopathy.